Effect of spironolactone on pharmacological treatment of nonalcoholic fatty liver disease.
Papaefthymiou A, Doulberis M, Karafyllidou K, Chatzimichael E, Deretzi G, Exadaktylos AK, Sampsonas F, Gelasakis A, Papamichos SI, Kotronis G, Gialamprinou D, Vardaka E, Polyzos SA, Kountouras J.
Papaefthymiou A, et al. Among authors: papamichos si.
Minerva Endocrinol (Torino). 2023 Sep;48(3):346-359. doi: 10.23736/S2724-6507.21.03564-8. Epub 2021 Oct 20.
Minerva Endocrinol (Torino). 2023.
PMID: 34669319